IMARA(US:IMRA)2025-11-12 21:10Financial Position - As of September 30, 2025, Enliven Therapeutics had cash, cash equivalents, and marketable securities totaling $477.6 million, providing a cash runway into the first half of 2029[9]. Research and Development - Research and development (R&D) expenses for Q3 2025 were $18.2 million, a decrease from $21.3 million in Q3 2024, representing a reduction of approximately 14.5%[9]. - The company completed enrollment of the randomized Phase 1b cohorts of the ENABLE trial for ELVN-001 in chronic myeloid leukemia (CML) and is on track to initiate a Phase 3 pivotal trial in 2026[1][3]. - ELVN-001 is designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for CML patients, and has shown potential as a selective active-site inhibitor[4][10]. - Enliven presented data from the ENABLE Phase 1a/1b clinical trial at multiple medical meetings, highlighting the strength of the data and community support for ELVN-001[3][4]. - The company plans to present additional data from the ENABLE trial at the 67th Annual American Society of Hematology (ASH) meeting in December 2025[5]. Operating Expenses - General and administrative (G&A) expenses for Q3 2025 were $6.9 million, an increase from $5.8 million in Q3 2024, reflecting a rise of approximately 19%[9]. - Total operating expenses for Q3 2025 were $25.1 million, down from $27.1 million in Q3 2024, marking a decrease of approximately 7.3%[17]. Net Loss - Enliven reported a net loss of $20.1 million for Q3 2025, compared to a net loss of $23.2 million for Q3 2024, indicating an improvement of about 13.4%[9]. Share Information - The weighted-average shares outstanding for Q3 2025 were 62,094, compared to 48,267 for Q3 2024, indicating an increase in shares[17].